Goserelin Can Inhibit Ovarian Cancer Proliferation and Simultaneously Protect Ovarian Function from Cisplatin: an in Vitro and in Vivo Study.

Ying Zhang,Jing Xin Ding,Xiang Tao,Zhi Ying Lu,Jia,Wei,Ke Qin Hua
DOI: https://doi.org/10.1179/1973947813y.0000000069
2013-01-01
Journal of Chemotherapy
Abstract:This study investigates whether goserelin can inhibit ovarian cancer proliferation and protect ovarian function from cisplatin (CDDP). We evaluated proliferation and AKT phosphorylation in goserelin-treated ES-2 and SKOV3-ip ovarian cancer cells. Anti-Müllerian hormone (AMH) in human granulosa cells (hGCs) cotreated with goserelin and CDDP was measured by ELISA. Tumour volumes, Ki-67 expression, estrus, follicles, ovarian volumes, and serum AMH were compared in nude mice bearing transplanted tumours treated with goserelin and/or CDDP. Our results showed that goserelin inhibited cellular proliferation and AKT phosphorylation in vitro, and inhibited tumour growth and Ki-67 expression in vivo. Goserelin and CDDP cotreatment decreased the estrus cycles of the nude mice and prolonged estrus duration. Goserelin abrogated the CDDP-induced down-regulation of primary and preantral follicle percentage and ovarian volume. Goserelin increased AMH secretion in vitro and in vivo. In conclusion, goserelin inhibited ovarian cancer proliferation and simultaneously protected ovarian function from CDDP.
What problem does this paper attempt to address?